Jérôme Rey

Centre National de la Recherche Scientifique — France

Medicine · Health Sciences

32h-index3.4kcitations170works0.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(71), Myeloproliferative Neoplasms: Diagnosis and Treatment(40), Hematopoietic Stem Cell Transplantation(27), Immune Cell Function and Interaction(24), Chronic Myeloid Leukemia Treatments(22)

Publications170 total

Dual transfusion independence and spleen volume reduction is associated with overall survival in patients with myelofibrosis treated with momelotinib: Post hoc analyses of SIMPLIFY-1 and MOMENTUM
Blood·2025Open Access
Development and Validation of the FIP Score for the Screening of FIP1L1::PDGFRA-Associated Hypereosinophilic Syndrome
The Journal of Allergy and Clinical Immunology In Practice·2025
POSTER: MPN-1036 Impact of Dual Spleen Response and Transfusion Independence on Survival in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia Treated With Momelotinib: A Subgroup Analysis of SIMPLIFY-1
Clinical Lymphoma Myeloma & Leukemia·2025
MPN-1036: Impact of Dual Spleen Response and Transfusion Independence on Survival in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia Treated With Momelotinib: A Subgroup Analysis of SIMPLIFY-1
Clinical Lymphoma Myeloma & Leukemia·2025
Gene expression-based rationale for investigating CDK4/6 inhibitors in primitive myelofibrosis
Leukemia·2025Open Access
Outcomes of Elderly Patients Admitted to the Intensive Care Unit for Newly Diagnosed Acute Myeloid Leukemia
European Journal Of Haematology·2025Open Access
249P Neoadjuvant chemotherapy in inflammatory breast cancer: A meta-analysis of 10 trials of the German Breast Group (GBG)
Annals of Oncology·2024Open Access
Venetoclax‐based non‐intensive induction followed by allogenic stem‐cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics
European Journal Of Haematology·2024Open Access
Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia
Leukemia Research·2024· 4 citedOpen Access
<i>CALR</i>‐mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM
American Journal of Hematology·2024· 3 citedOpen Access
Azacitidine–venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients
European Journal Of Haematology·2023· 9 citedOpen Access
Clinical, Cytogenetic and Molecular Characterization of a 96 MDS and AML Cohort with <i>TP53</i> Mutation
Blood·2023Open Access
CPX-351 in Patients with Newly Diagnosed Post Myeloproliferative Neoplasms Acute Myeloid Leukemia
Blood·2023· 2 cited
Poor Prognosis of SRSF2 Gene Mutations in Patients Treated with Venetoclax-Azacitidine (VEN-AZA) for Newly Diagnosed Acute Myeloid Leukemia. a Multicentric Real-Life Study of 117 Patients
Blood·2023· 1 citedOpen Access
POSTER: AML-110 Outcome of Acute Myeloid Leukemia Relapse After Allogenic Stem Cell Transplantation: A Single-Institution Retrospective Study
Clinical Lymphoma Myeloma & Leukemia·2023Open Access
AML-110 Outcome of Acute Myeloid Leukemia Relapse After Allogenic Stem Cell Transplantation: A Single-Institution Retrospective Study
Clinical Lymphoma Myeloma & Leukemia·2023
PB1844: REAL: A RETROSPECTIVE STUDY OF THE CLINICO-BIOLOGICAL FEATURES OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES PATIENTS INCLUDED IN AN EARLY PHASE TRIAL AT A COMPREHENSIVE CANCER CENTER.
HemaSphere·2023Open Access
Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice
eJHaem·2023· 6 citedOpen Access
Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group
Blood·2022· 1 cited
Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
Cancers·2022· 56 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Norbert Vey(24), Anne Murati(11), Aude Charbonnier(11), Daniel Birnbaum(10), Julien Mozziconacci(10), Daniel Olive(10), Raynier Devillier(8), Jean‐Jacques Kiladjian(7), Lydia Roy(7), José Adélaı̈de(7), Max Chaffanet(7), Véronique Gelsi‐Boyer(7), Evelyne D’Incan(7), Cyril Fauriat(7), Didier Blaise(7), Nadine Carbuccia(6), Christine Arnoulet(6), Mandy Brecqueville(5), Colombe Saillard(5), Jean‐Christophe Ianotto(5)